Abstract 243P
Background
Cervical cancer ranks as 2nd leading cause of female cancer in Indonesia. Early detection of cervical cancer is crucial for early treatment and reduce risk of mortality. Despite the evidence of cervical cancer screening is associated with decrease mortality from this disease, the uptake for cervical cancer screening among Indonesian women in suburban area of Banten remains low. The aim of this study is to discover factors that associate with uptake of cervical cancer screening and report on cervical cancer prevalence among women in suburban area of Banten.
Methods
This is a cross sectional study that took the mass screening in 3 different primary health care in Banten, Indonesia. We included female who had never done screening for cervical cancer and aged 21-65 years old. Cervical sample were collected for Papanicolaou smear and evaluated by pathologist.
Results
Pap smears of 309 females were taken. It was observed that 74,11% (n = 229) of females were negative for cervical intraepithelial lesion or malignancy. Our data showed that 13,5% (n = 42) had bacterial vaginosis, 6.14% (n = 19) had candida infection. Respectively ,for low grade squamous intraepithelial lesion (LSIL) and high grade intraepithelial lesion were 2,26%( n = 7) and 1,61 % (n = 5). Cervical cancer was positive for 0.97% (n = 3) and 1.29% (n = 4) had atropic vaginitis. The significant predictor for uptake of cervical cancer screening were being married, older age, and knowing a person with cervical cancer with p value 0.004, 0,037 and <0,001. The only significant factor that contribute to reduce uptake of screening is did not know where to go for screening and the price of screening with p value of 0,024 and 0.017.
Conclusions
Mass screening and public education is a crucial step to reduce morbidity and mortality of cervical cancer. Poor hygiene environment in suburban region increase incidence of infection that lead to causative factors for cervical cancer. Intensification of primary health care for cancer screening is needed to reduce the national burden of cervical cancer in Indonesia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Pelita Harapan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract